Target type: cellularcomponent
An integrin complex that comprises one alpha4 subunit and one beta1 subunit. [PMID:12297042]
The integrin alpha4-beta1 complex is a transmembrane receptor that mediates cell adhesion to extracellular matrix components such as vascular cell adhesion molecule 1 (VCAM-1) and fibronectin. It plays a critical role in various cellular processes, including leukocyte migration, angiogenesis, and tumor metastasis. The cellular component of the integrin alpha4-beta1 complex is composed of two subunits: the alpha4 subunit and the beta1 subunit. Each subunit consists of a large extracellular domain, a transmembrane domain, and a cytoplasmic domain. The extracellular domains of both subunits interact with each other to form a heterodimer that binds to its ligands. The cytoplasmic domains of both subunits interact with intracellular proteins, including talin, kindlin, and paxillin, which link the integrin to the actin cytoskeleton. These interactions are essential for integrin-mediated signal transduction and cell migration. The integrin alpha4-beta1 complex is localized to focal adhesions, which are specialized structures that form at the interface between cells and the extracellular matrix. These adhesions provide a mechanical link between the cell and its environment and act as platforms for signal transduction. Integrin alpha4-beta1 complexes are also found in other cellular compartments, such as the cell membrane, the Golgi apparatus, and the endoplasmic reticulum.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Integrin alpha-4 | An integrin alpha-4 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P13612] | Homo sapiens (human) |
| Integrin beta-1 | An integrin beta-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P05556] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| haloperidol | haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
| 1,3-ditolylguanidine | 1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the brain | toluenes | |
| tirofiban | tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME. | L-tyrosine derivative; piperidines; sulfonamide | anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist |
| arginyl-glycyl-aspartic acid | arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system | oligopeptide | |
| arginyl-glycyl-aspartyl-serine | arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets | ||
| glycyl-arginyl-glycyl-aspartyl-serine | glycyl-arginyl-glycyl-aspartyl-serine: synthetic peptide from fibronectins; inhibits experimental metastasis of murine melanoma cells | ||
| d-arg-gly-asp-trp | arginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide | ||
| l 738167 | L 738167: structure in first source | ||
| cilengitide | Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells | oligopeptide | |
| l 734217 | L 734217: fibrinogen receptor antagonist; structure given in first source | ||
| cyclopamine | piperidines | glioma-associated oncogene inhibitor | |
| arginyl-glycyl-aspartyl-phenylalanine | |||
| cyclic(arg-gly-asp-d-phe-val) | |||
| mk-0429 | |||
| mocetinostat | mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11). mocetinostat: undergoing phase II clinical trials for treatment of cancer | aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline | antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent |
| tr 14035 | N-(2,6-dichlorobenzoyl)-4-(2',6'-bismethoxyphenyl)phenylalanine: TR-14035 is the (L)-isomer; an antagonist of both alpha4beta1 and beta7 integrins; structure in first source | ||
| bio 1211 | BIO 1211: integrin alpha4beta1 inhibitor; structure in first source |